Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hysterectomy | 7 | 2020 | 55 | 1.760 |
Why?
|
| Gynecologic Surgical Procedures | 4 | 2019 | 50 | 1.320 |
Why?
|
| Menorrhagia | 3 | 2017 | 4 | 1.160 |
Why?
|
| Leiomyoma | 3 | 2018 | 16 | 1.160 |
Why?
|
| Venous Thromboembolism | 2 | 2020 | 29 | 1.120 |
Why?
|
| Preoperative Care | 3 | 2019 | 129 | 1.110 |
Why?
|
| Laparoscopy | 7 | 2018 | 194 | 1.020 |
Why?
|
| Endometriosis | 2 | 2017 | 103 | 0.880 |
Why?
|
| Endometrial Ablation Techniques | 3 | 2017 | 5 | 0.760 |
Why?
|
| Gynecology | 2 | 2019 | 20 | 0.670 |
Why?
|
| Uterine Neoplasms | 2 | 2018 | 32 | 0.660 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 28 | 0.640 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 19 | 0.550 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 69 | 0.550 |
Why?
|
| Postoperative Complications | 3 | 2020 | 850 | 0.550 |
Why?
|
| Critical Pathways | 1 | 2018 | 52 | 0.550 |
Why?
|
| Perioperative Care | 1 | 2018 | 57 | 0.540 |
Why?
|
| Cecal Diseases | 1 | 2017 | 2 | 0.530 |
Why?
|
| Appendix | 1 | 2017 | 6 | 0.530 |
Why?
|
| Hysteroscopy | 1 | 2017 | 4 | 0.530 |
Why?
|
| Female | 23 | 2020 | 21532 | 0.520 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 205 | 0.500 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 265 | 0.490 |
Why?
|
| Models, Theoretical | 1 | 2017 | 146 | 0.490 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 136 | 0.480 |
Why?
|
| Anticoagulants | 1 | 2016 | 143 | 0.450 |
Why?
|
| Endometrium | 1 | 2016 | 183 | 0.440 |
Why?
|
| Humans | 25 | 2020 | 34562 | 0.430 |
Why?
|
| Abdominal Wall | 1 | 2014 | 24 | 0.430 |
Why?
|
| Uterus | 3 | 2020 | 106 | 0.420 |
Why?
|
| Uterine Cervical Diseases | 1 | 2013 | 2 | 0.410 |
Why?
|
| Adult | 14 | 2020 | 10030 | 0.400 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 58 | 0.390 |
Why?
|
| Surgical Mesh | 1 | 2013 | 50 | 0.390 |
Why?
|
| Middle Aged | 10 | 2020 | 12726 | 0.280 |
Why?
|
| Hysterectomy, Vaginal | 2 | 2018 | 7 | 0.280 |
Why?
|
| Levonorgestrel | 2 | 2017 | 4 | 0.270 |
Why?
|
| Databases, Factual | 2 | 2020 | 380 | 0.270 |
Why?
|
| Obesity | 3 | 2020 | 1246 | 0.260 |
Why?
|
| Treatment Outcome | 5 | 2017 | 3623 | 0.240 |
Why?
|
| United States | 4 | 2020 | 4278 | 0.220 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2004 | 18 | 0.210 |
Why?
|
| Water | 1 | 2004 | 70 | 0.200 |
Why?
|
| RNA | 1 | 2004 | 100 | 0.200 |
Why?
|
| Organ Size | 2 | 2020 | 236 | 0.190 |
Why?
|
| DNA | 1 | 2004 | 235 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2020 | 1910 | 0.170 |
Why?
|
| Contraceptive Agents | 1 | 2020 | 4 | 0.160 |
Why?
|
| Fertilization | 1 | 2020 | 5 | 0.160 |
Why?
|
| Risk Factors | 3 | 2018 | 4137 | 0.160 |
Why?
|
| Patient Admission | 1 | 2019 | 59 | 0.150 |
Why?
|
| Teaching | 1 | 2019 | 65 | 0.150 |
Why?
|
| Postoperative Care | 1 | 2019 | 80 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 98 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 103 | 0.140 |
Why?
|
| Incidence | 2 | 2020 | 1290 | 0.140 |
Why?
|
| Dyspareunia | 2 | 2017 | 7 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 260 | 0.140 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2017 | 5 | 0.130 |
Why?
|
| Motor Skills | 1 | 2017 | 16 | 0.130 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 15 | 0.130 |
Why?
|
| Intraoperative Period | 1 | 2017 | 44 | 0.130 |
Why?
|
| Adolescent | 4 | 2020 | 3805 | 0.130 |
Why?
|
| Appendectomy | 1 | 2017 | 19 | 0.130 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 35 | 0.130 |
Why?
|
| Young Adult | 3 | 2020 | 2831 | 0.130 |
Why?
|
| Vagina | 1 | 2017 | 61 | 0.130 |
Why?
|
| User-Computer Interface | 1 | 2017 | 55 | 0.130 |
Why?
|
| Internship and Residency | 2 | 2019 | 330 | 0.130 |
Why?
|
| Pelvic Organ Prolapse | 2 | 2017 | 48 | 0.130 |
Why?
|
| Learning | 1 | 2017 | 88 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2016 | 19 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2017 | 256 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 51 | 0.120 |
Why?
|
| Peritoneal Cavity | 1 | 2016 | 6 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2017 | 149 | 0.120 |
Why?
|
| Abdominal Cavity | 1 | 2016 | 6 | 0.120 |
Why?
|
| Curriculum | 1 | 2017 | 217 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3825 | 0.110 |
Why?
|
| Hysterotomy | 1 | 2014 | 2 | 0.110 |
Why?
|
| Pregnancy, Ectopic | 1 | 2014 | 8 | 0.110 |
Why?
|
| Patient Selection | 1 | 2016 | 291 | 0.110 |
Why?
|
| Comorbidity | 1 | 2016 | 596 | 0.110 |
Why?
|
| Cicatrix | 1 | 2014 | 41 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2018 | 954 | 0.110 |
Why?
|
| Prevalence | 1 | 2017 | 1034 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2017 | 349 | 0.110 |
Why?
|
| Cathartics | 1 | 2014 | 5 | 0.110 |
Why?
|
| Enema | 1 | 2014 | 6 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 922 | 0.100 |
Why?
|
| Phosphates | 1 | 2014 | 28 | 0.100 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2014 | 66 | 0.100 |
Why?
|
| Vaginal Discharge | 1 | 2013 | 3 | 0.100 |
Why?
|
| Sacrum | 1 | 2013 | 23 | 0.100 |
Why?
|
| Cervix Uteri | 1 | 2013 | 28 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 431 | 0.100 |
Why?
|
| Overweight | 1 | 2015 | 289 | 0.100 |
Why?
|
| North Carolina | 1 | 2017 | 1613 | 0.100 |
Why?
|
| Time Factors | 2 | 2016 | 2353 | 0.090 |
Why?
|
| Cues | 1 | 2012 | 65 | 0.090 |
Why?
|
| Quality of Life | 2 | 2017 | 1032 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 491 | 0.090 |
Why?
|
| Nephrotic Syndrome | 2 | 2008 | 12 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2016 | 1508 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 988 | 0.070 |
Why?
|
| Cocaine | 1 | 2012 | 355 | 0.070 |
Why?
|
| Levamisole | 1 | 2008 | 2 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2019 | 2463 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 63 | 0.070 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2007 | 38 | 0.060 |
Why?
|
| Brain | 1 | 2012 | 1032 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2017 | 585 | 0.060 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2004 | 5 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 23 | 0.050 |
Why?
|
| Thermodynamics | 1 | 2004 | 57 | 0.050 |
Why?
|
| Temperature | 1 | 2004 | 65 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2004 | 52 | 0.050 |
Why?
|
| Base Sequence | 1 | 2004 | 265 | 0.050 |
Why?
|
| Remission Induction | 2 | 2015 | 97 | 0.040 |
Why?
|
| Research Design | 1 | 2004 | 337 | 0.040 |
Why?
|
| Pregnancy | 2 | 2015 | 1069 | 0.040 |
Why?
|
| Abortion, Induced | 1 | 2020 | 7 | 0.040 |
Why?
|
| Contraception | 1 | 2020 | 13 | 0.040 |
Why?
|
| Temperament | 1 | 2019 | 1 | 0.040 |
Why?
|
| Attitude to Computers | 1 | 2019 | 17 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 113 | 0.040 |
Why?
|
| Mentors | 1 | 2019 | 35 | 0.040 |
Why?
|
| Self Concept | 1 | 2019 | 47 | 0.040 |
Why?
|
| Career Choice | 1 | 2019 | 45 | 0.040 |
Why?
|
| Women's Health | 1 | 2020 | 242 | 0.040 |
Why?
|
| Ligaments | 1 | 2017 | 16 | 0.030 |
Why?
|
| Sexuality | 1 | 2017 | 14 | 0.030 |
Why?
|
| Students, Medical | 1 | 2019 | 136 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 55 | 0.030 |
Why?
|
| Decision Trees | 1 | 2017 | 31 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 480 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 939 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 197 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 126 | 0.030 |
Why?
|
| Glucocorticoids | 2 | 2008 | 154 | 0.030 |
Why?
|
| Cytological Techniques | 1 | 2016 | 17 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 24 | 0.030 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2015 | 3 | 0.030 |
Why?
|
| Dactinomycin | 1 | 2015 | 13 | 0.030 |
Why?
|
| Vincristine | 1 | 2015 | 26 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 49 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 43 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 71 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 29 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 486 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2014 | 122 | 0.030 |
Why?
|
| Reoperation | 1 | 2014 | 265 | 0.020 |
Why?
|
| Aged | 2 | 2018 | 11022 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 2012 | 30 | 0.020 |
Why?
|
| Wakefulness | 1 | 2012 | 30 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2012 | 139 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 193 | 0.020 |
Why?
|
| Reward | 1 | 2012 | 70 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 245 | 0.020 |
Why?
|
| Conditioning, Operant | 1 | 2012 | 125 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2012 | 208 | 0.020 |
Why?
|
| Child | 2 | 2008 | 2614 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 1606 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2012 | 923 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 1946 | 0.020 |
Why?
|
| Male | 3 | 2012 | 20740 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2008 | 74 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2007 | 42 | 0.020 |
Why?
|
| Age of Onset | 1 | 2007 | 95 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2007 | 109 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 318 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 1393 | 0.020 |
Why?
|
| Biopsy | 1 | 2007 | 273 | 0.010 |
Why?
|
| African Continental Ancestry Group | 1 | 2007 | 367 | 0.010 |
Why?
|
| Sex Factors | 1 | 2007 | 708 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 803 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2007 | 926 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 1355 | 0.010 |
Why?
|
| European Continental Ancestry Group | 1 | 2007 | 1176 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 2367 | 0.010 |
Why?
|
| Hispanic Americans | 1 | 2007 | 948 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 8579 | 0.010 |
Why?
|